301 filings
Page 6 of 16
8-K
k47cx aq9l
8 May 20
Regulation FD Disclosure
7:00am
8-K
2d10uhfj2hf7zx0 kuen
4 May 20
Entry into a Material Definitive Agreement
7:00am
8-K
848r5zz9
15 Apr 20
Other Events
6:31am
8-K
m0g6v62 lhp5vv46i
13 Mar 20
Regulation FD Disclosure
5:00pm
8-K
jxvyo
7 Feb 20
Departure of Directors or Certain Officers
4:05pm
8-K
sgu81zxij 50q
4 Dec 19
Regulation FD Disclosure
9:02am
8-K
4qz0xwbf4l7szvhh8apa
2 Dec 19
Oragenics, Inc. Announces Completion of Enrollment of Its Phase 2 Clinical Trial for AG013 In Oral Mucositis
8:59am
8-K
elskd4 9yv
22 Oct 19
Oragenics, Inc. to Present at the Bio Investor Forum
8:33am
8-K
92mgwhm50d
30 Sep 19
Oragenics Presents Interim Data on The AG013 Phase 2 Clinical Trial at the European Society for Medical Oncology Congress 2019
8:07am
8-K
rso9ddzoq s9l
25 Sep 19
Oragenics, Inc. Announces Phase 2 Clinical Trial of AG013
8:53am
8-K
73hhkloeez7hdj1
23 Sep 19
Oragenics, Inc. to Present Interim Data on AG013 at the European Society of
9:02am
8-K
5h3ik
6 Sep 19
Regulation FD Disclosure
5:20pm
8-K
0kgbvc1ji kcgj6
21 Jun 19
Submission of Matters to a Vote of Security Holders
4:48pm
8-K
xh00zh50
25 Mar 19
Oragenics Announces Closing of $12.5 Million Underwritten Public Offering
4:32pm
8-K
rnf4m 9wvfxl
21 Mar 19
Oragenics Announces Pricing of $12.5 Million Underwritten Public Offering
9:26am
8-K
r2fzyw
20 Mar 19
Organics Announces Proposed Underwritten Public Offering
5:28pm
8-K
mdf7 qncafdc2vd
15 Mar 19
Oragenics, Inc. Announces Enrollment of 60th Patient in Clinical Trial
4:40pm
8-K
foe5rjn56 v59gpv0
22 Feb 19
Departure of Directors or Certain Officers
5:01pm
8-K
3uq31i k9vrax7nuqx
21 Dec 18
Departure of Directors or Certain Officers
4:27pm
8-K
qc6j7d v4
3 Dec 18
Regulation FD Disclosure
5:27pm